CompletedPhase 1/2

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

United States18 participantsStarted 2019-01-31

Plain-language summary

The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see if it is more sensitive to localize the source of the hormone, which has caused the low phosphate levels.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (18 years of age or older) seen at Mayo Clinic, Rochester for FGF23 mediated osteomalacia between 1/1/2000 and 1/30/2018 who provide informed consent to participate in the study. Exclusion Criteria: * Pregnant * Prisoners * Subjects diagnosed with heritable hypophosphatemic rickets/osteomalacia * Subjects who do not consent for the study or withdraw consent during the duration of the study. * Subjects in whom tumor localization and successful resection has already occurred.

What they're measuring

Number of Participants With Positive Localization of Phosphaturic Mesenchymal Tumors (PMTs)

Timeframe: One year

Trial details

NCT IDNCT03736564

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-31

Results submitted2025-03-24

View on ClinicalTrials.gov More Osteomalacia trials